AT207042B - Process for the production of pharmaceutical preparations which contain purines and / or purine derivatives - Google Patents

Process for the production of pharmaceutical preparations which contain purines and / or purine derivatives

Info

Publication number
AT207042B
AT207042B AT323857A AT323857A AT207042B AT 207042 B AT207042 B AT 207042B AT 323857 A AT323857 A AT 323857A AT 323857 A AT323857 A AT 323857A AT 207042 B AT207042 B AT 207042B
Authority
AT
Austria
Prior art keywords
production
pharmaceutical preparations
purine derivatives
purines
sep
Prior art date
Application number
AT323857A
Other languages
German (de)
Original Assignee
Chemiewerk Homburg Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemiewerk Homburg Ag filed Critical Chemiewerk Homburg Ag
Application granted granted Critical
Publication of AT207042B publication Critical patent/AT207042B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

   <Desc/Clms Page number 1> 
 



  Verfahren zur Herstellung von pharmazeutischen Präparaten, die Purine und bzw. oder Purinderivate enthalten 
 EMI1.1 
 
 EMI1.2 
 
<tb> 
<tb> wasserlöslichenWasserlöslichkeit <SEP> in <SEP> So <SEP> 
<tb> Theophyllin <SEP> 0, <SEP> 5 <SEP> 
<tb> Coffein <SEP> 1, <SEP> 5 <SEP> 
<tb> Adenosin <SEP> 0, <SEP> 5 <SEP> 
<tb> 7- <SEP> (6 <SEP> -Aminoäthyl) <SEP> -theophyllin <SEP> über <SEP> 50
<tb> 1- <SEP> (ss-Äthylaminoäthyl)-theobromin. <SEP> HCI <SEP> über <SEP> 50
<tb> 1- <SEP> (8 <SEP> -Diäthylaminoäthyl) <SEP> -theobrominrhodanid <SEP> über <SEP> 18. <SEP> 
<tb> 
 

 <Desc/Clms Page number 2> 

 



   Beispiel 1: 5,6g 7-(ss-Aminoäthyl)-theophyllin werden mit 5, 0 g Theophyllin und zu 100 g Lösung mit Wasser vermischt. Es entsteht eine stabile Lösung. 



   Beispiel 2: 10,0 g 1-(ss-Diäthylaminoäthyl)-theobrominrhodanid werden mit 5, 0 g Coffein und zu 100 g Lösung mit Wasser vermischt. Es entsteht eine stabile Lösung. 
 EMI2.1 
 
3 : 30, 0g l- (ss-Äthylaminoäthyl)-theobromir. HCJ werdenzu 100 g Lösung mit Wasser vermischt. Es entsteht eine stabile Lösung.



   <Desc / Clms Page number 1>
 



  Process for the production of pharmaceutical preparations which contain purines and / or purine derivatives
 EMI1.1
 
 EMI1.2
 
<tb>
<tb> water soluble water solubility <SEP> in <SEP> So <SEP>
<tb> Theophylline <SEP> 0, <SEP> 5 <SEP>
<tb> Caffeine <SEP> 1, <SEP> 5 <SEP>
<tb> Adenosine <SEP> 0, <SEP> 5 <SEP>
<tb> 7- <SEP> (6 <SEP> -aminoethyl) <SEP> -theophylline <SEP> over <SEP> 50
<tb> 1- <SEP> (ss-ethylaminoethyl) -theobromine. <SEP> HCI <SEP> via <SEP> 50
<tb> 1- <SEP> (8 <SEP> -Diethylaminoäthyl) <SEP> -theobromine rhodanide <SEP> via <SEP> 18. <SEP>
<tb>
 

 <Desc / Clms Page number 2>

 



   Example 1: 5.6 g of 7- (ss-aminoethyl) -theophylline are mixed with 5.0 g of theophylline and 100 g of solution with water. A stable solution is created.



   Example 2: 10.0 g of 1- (ss-diethylaminoethyl) -theobromine rhodanide are mixed with 5.0 g of caffeine and 100 g of solution with water. A stable solution is created.
 EMI2.1
 
3:30, 0g l- (ss-ethylaminoethyl) -theobromir. HCJ are mixed with water to make 100 g of the solution. A stable solution is created.

Claims (1)

PATENTANSPRUCH : Verfahren zur Herstellung von pharmazeutischen Präparaten, wie wasserlöslichen Pulvern, Tabletten und Suppositorien sowie konzentrierten und beständigen wässerigen Lösungen, die Purine und bzw. oder Purinderivate enthalten, dadurch gekennzeichnet, dass zur Erhöhung der Löslichkeit und Stabilität der Präparate aminoalkyllerte Alkylxanthine, wie aminoalkylierte Theophyllim oder aminoalkylicrte Thsobro- mine, oder deren Mischungen bzw. die jeweiligen Salze Purinen, wie Theophyllin, Theobromin, Coffein, Adenin, Adenosin oder deren Mischungen, zugesetzt werden. PATENT CLAIM: Process for the production of pharmaceutical preparations, such as water-soluble powders, tablets and suppositories as well as concentrated and stable aqueous solutions containing purines and / or purine derivatives, characterized in that aminoalkylated alkylxanthines, such as aminoalkylated theophyllime or aminoalkylicrte, to increase the solubility and stability of the preparations Thsobromines, or mixtures thereof or the respective salts purines, such as theophylline, theobromine, caffeine, adenine, adenosine or mixtures thereof, are added.
AT323857A 1956-05-17 1957-05-16 Process for the production of pharmaceutical preparations which contain purines and / or purine derivatives AT207042B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE207042X 1956-05-17

Publications (1)

Publication Number Publication Date
AT207042B true AT207042B (en) 1960-01-11

Family

ID=5793496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT323857A AT207042B (en) 1956-05-17 1957-05-16 Process for the production of pharmaceutical preparations which contain purines and / or purine derivatives

Country Status (1)

Country Link
AT (1) AT207042B (en)

Similar Documents

Publication Publication Date Title
GB1183520A (en) Porous high silica glass
AT207042B (en) Process for the production of pharmaceutical preparations which contain purines and / or purine derivatives
DE686413C (en) Process for the production of concentrated theophylline and caffeine solutions
US4117132A (en) Process for the production of stabilized pure theophylline in neutral, aqueous solution
AT206587B (en) Process for the production of pharmaceutical preparations which contain oxyalkylated theophylline and / or oxyalkylated theobromo compounds
GB901704A (en) Water-soluble digoxin preparations and concentrated and stable aqueous solutions thereof
ES482742A1 (en) Substituted 2-phenylamino-imidazolines-(2), their acid addition salts, medicaments containing them and processes for their preparation.
GB817624A (en) Molecular compounds of purines and a method of production
DK105206C (en) Process for the preparation of pyrimidine carboxylic acid (4) derivatives or pyrimidine thiocarboxylic acid (4) derivatives or salts thereof.
GB731971A (en) Improvements in and relating to an aqueous solution of 4-dimethylaminoantipyrine andprocess for the preparation thereof
DE858455C (en) Process for the production of neutral or weakly acidic solutions of substituted xanthines
GB774598A (en) Improvements relating to titanium or titanium base alloys
AT205668B (en)
GB1322119A (en) Recovery of ammonium sulphate
DE871951C (en) Process for the preparation of rich aqueous solutions of dihalodioxybenzilen
DE868493C (en) Process for the production of aqueous solutions of p-aminobenzene sulfonamide or of decoctions of the same
GB902377A (en) Stable solutions containing vitamin b
DE1914822C3 (en) External agent to prevent irritation, inflammation and sensitization
AT190635B (en) Process for the production of water-soluble powders, tablets and suppositories as well as concentrated and stable aqueous solutions containing oxyalkylated theophylline and / or theobromine compounds
DE967872C (en) Process for the production of aqueous solutions of drugs that are poorly soluble in water
DE765191C (en) Process for the production of solid, water-soluble aluminum acetate
GB883259A (en) Improvements in or relating to vitamin compositions comprising cobalamine and ascorbic acid
DE698815C (en) Process for the production of durable, high-content solutions of the polyoxyalkylisoalloxazines
DE841331C (en) Process for the production of readily water-soluble molecular compounds of purine bodies that are poorly soluble in water
DE666266C (en) Process to increase the water solubility of azo compounds